btig

In a note released Thursday, BTIG analyst Dane Leone initiated coverage of Affymetrix, Inc. (NASDAQ: AFFX) with a Neutral rating and a near-term trading range of $7.50 to $10. Leone commented, "In our view, solid execution by the management team has moved AFFX from being a ‘...

Analysts at BTIG downgraded shares of J.C. Penney (NYSE: JCP) from Buy to Neutral Thursday, following achievement of price target. Analysts view the recent performance of shares validates their original thesis, which was J.C. Penney had sufficient capital resources to avoid bankruptcy and...

Sean Lavin of BTIG upgraded shares of Endologix (NASDAQ: ELGX) to Buy. What's notable about the upgrade is that just a few weeks ago on July 7 shares were downgraded to Neutral from Buy. Lavin's decision to return to a Buy rating follows a visit to the company's head office. The analyst notes...

Mark Palmer of BTIG upgraded shares of MBIA (NYSE: MBI) to Buy from Neutral with a $12 price target following Puerto Rico's electric power authority (PREPA) agreement with its creditors to delay a $671 million payment until March. Additionally, PREPA received from a group representing over...

Keurig Green Mountain's (NASDAQ: GMCR) 20 percent gain in second-quarter income was helped a lot by lower coffee and selling costs, both of which are soon expected to reverse themselves, an analyst said Thursday. Sales of the company's coffee and coffee makers grew six percent in the...

Following Thursday's second quarter earnings release, shares of Green Dot (NYSE: GDOT) have rallied 10 percent Friday. In response to the company's results and guidance, a number of analyst firms have issued notes detailing their opinion of the stock. BTIG - Buy, $31 Price Target...

In a report released Thursday, BTIG analyst Mark Palmer initiated coverage on Synchrony Financial (NYSE: SYF) with a Buy rating and $30 price target. Analysts at BTIG predict Synchrony shares to rise due to credit card spending projected to increase. A Nilson Report projects domestic consumer...

Allergan's (NYSE: AGN) strong showing in its recent second quarter suggests an acquirer may need to offer "north of $200 a share," one analyst said Tuesday. Valeant Pharmaceuticals' (NYSE: VRX) $53 billion unsolicited bid for Allergan was rejected last month. The bid equaled $...

BTIG analyst Sean Lavin initiated coverage on Masimo (NASDAQ: MASI) with a Buy rating and $32.00 price target. Lavin is optimistic on the medical technology company's future, seeing limited downside for the underperforming stock. The analyst wrote, “We see multiple things that could...

In a note released Tuesday, BTIG Equity Research analyst Sean Lavin M.D. initiated coverage on Intuitive Surgical (NASDAQ: ISRG) with a Neutral rating, but has yet to set a price target. Lavin explained he is optimistic on the long-term outlook of the stock, but sees near-term troubles. He...

Shares of Dr. Pepper Snapple (NYSE: DPS) are down Thursday morning after BTIG initiated the company with a Sell rating and $50 price target (19.8 percent downside). Analyst Theo Brito writes, “Despite whitespace for both Dr Pepper and Snapple, DPS is not gaining distribution. We believe...

Wall Street appeared comfortable with the latest big healthcare merger, this one the acquisition of Covidien (NYSE: COV) by Medtronic (NYSE: MDT), a deal which turns eyes to Johnson & Johnson (NYSE: JNJ). "We expect many investors will expect J&J to buy something in the cardiac...